Sumitomo Pharmaceuticals Company Limited

Dainippon Sumitomo Pharma Co., Ltd.

Kazuki Matsui

Naohito Ohashi

Masami Muraoka

Koji Morishita

Atsuyuki Kojima

Masatoshi Yuri

Hirohiko Hasegawa

Naonori Imazaki

Takaaki Yamamoto

Seiji Katayama

Masafumi Kitano

An optically active form of the quinazolinone derivatives represented by the general formula (1): [wherein Y represents a phenyl group or C2-C7 alkyl group; E represents &#x2014;CH&#x2550; or nitrogen atom; and R represents a C1-C4 alkyl group and so on], or pharmaceutically acceptable salts thereof, has a selective antagonism for the M3 muscarinic receptor and depressant action on the frequency of rhythmic bladder contractions, and it is useful for the treatment of pollakiuria and urinary incontinence.

Quinazolinone derivative

A compound represented by the formula (1): wherein R&#x2014;X&#x2014; indicates that 1 to 4 R&#x2014;X&#x2014; groups are present which may be the same or different,

Rho kinase inhibitors

Quinazolinone derivatives

This invention is to provide quinazolinone derivatives, and their acid salts and quaternary ammonium salts, having an effect of preventing or treating diseases caused by calcium ion overload in cells, such as ischemic heart disease, ischemic cerebral disease and ischemic renal disease, and their usage. The quinazolinone derivatives are represented by the formula: ##STR1## typically, T represents an oxygen atom; Y represents a phenyl or cyclohexyl group; R.sup.1 represents a hydrogen or chlorine atom; R.sup.2 represents a hydrogen atom; ring W represents a benzene or pyridine ring; Z represents a group of the formula: ##STR2##

Quinazolinone derivatives possessing calcium uptake inhibiting activity

Growing community of inventors

Sanda, Japan

Kazuki Matsui